Sermorelin tablets are compounded oral or oromucosal dosage forms, but they do not have the clinical evidence behind injected sermorelin. A swallowed tablet has to carry a 29-amino-acid peptide through digestive enzymes and across the intestinal wall. No human study has established reliable absorption by that route. Rapid-dissolve tablets and troches meant to dissolve in the mouth avoid some digestion, yet no peer-reviewed human study has established sermorelin-specific sublingual bioavailability. The dosage form is real; reliable systemic delivery remains unproven.
What sermorelin tablets actually are
The words oral and sublingual are often used as if they mean the same thing. They do not. The route depends on where the medication is intended to cross into the body, not simply where it starts.
| Label term | What it usually means | Evidence question |
|---|---|---|
| Tablet or pill | Swallowed for gastrointestinal absorption | Does intact peptide survive digestion and cross the intestine? |
| RDT or rapid-dissolve tablet | Breaks apart quickly in the mouth; some or all may be swallowed | Was absorption through the oral mucosa actually measured? |
| Troche or lozenge | Dissolves slowly against the cheek or under the tongue | Is the formulation validated for consistent transmucosal delivery? |
| Sublingual | Intended to be absorbed through tissue under the tongue | Are there human pharmacokinetic data for this peptide and formulation? |
Those distinctions matter because compounded formulations can differ in strength, excipients and intended route. A word such as “troche” describes a format. It does not establish how much intact sermorelin reaches circulation.
Do sermorelin tablets work when swallowed?
There is no adequate human evidence that a conventional swallowed sermorelin tablet produces reliable systemic exposure. This is pharmacology, not a judgment about convenience. Sermorelin is the active 29-amino-acid fragment of growth-hormone-releasing hormone. Like other unprotected peptides, it can be cut apart by enzymes before absorption, and its size and water-loving chemistry make passage through the intestinal lining difficult.
A 2013 review of oral protein and peptide delivery reported bioavailability typically below 1% to 2% for macromolecules as a class because the gastrointestinal epithelium creates both biochemical and physical barriers (Muheem et al., International Journal of Pharmaceutics, 2013). That class-level range is useful context, but it is not a measured sermorelin number. A precise percentage for an oral sermorelin product needs product-specific human pharmacokinetic testing.
Does sublingual sermorelin solve the problem?
Sublingual delivery bypasses the stomach only for the portion that crosses the tissue under the tongue. Material dissolved into saliva and swallowed still meets the gastrointestinal barriers. Avoiding the stomach also does not make oral mucosa freely permeable to a peptide.
A peer-reviewed review of buccal peptide delivery found that peptides are generally poorly absorbed through oral mucosa because of molecular size, hydrophilicity and low membrane permeability; metabolism in that tissue adds another barrier (Veuillez et al., European Journal of Pharmaceutics and Biopharmaceutics, 2001). Penetration enhancers, enzyme inhibitors and specialized adhesive systems are formulation strategies, not proof that any particular troche works.
For sermorelin specifically, no peer-reviewed human pharmacokinetic trial has established the bioavailability, consistency or clinical effect of a sublingual RDT or troche. Claims that a mouth-dissolving product “bypasses digestion” answer only part of the question. The missing number is how much intact peptide enters circulation from that exact formulation. The same question applies to the nasal route, where one study did measure it: sermorelin nasal spray walks through what that study found.
Why injection remains the studied route
The historical sermorelin record is built on intravenous and subcutaneous administration. A 1994 intravenous study in 10 men measured a 4.3 ± 1.4-minute disappearance half-time for GHRH(1-29)NH2 (Soule et al., Journal of Clinical Endocrinology & Metabolism, 1994). That finding describes rapid clearance after the peptide is already in circulation; it does not measure oral absorption. In one small 1989 study, eight children with partial growth-hormone insufficiency received continuous subcutaneous GHRH(1-29)NH2; the investigators measured growth-hormone secretion and growth velocity over three and six months (Brain et al., Acta Paediatrica Scandinavica Supplement, 1989). That study does not establish outcomes for adults seeking wellness treatment. It does show that the studied molecule reached the body by injection, not by tablet.
The former brand Geref was also an injection. FDA records show that its two applications covered a pediatric treatment product and a diagnostic product, both injectable. That is why a comparison of sermorelin injections with tablets is mainly a comparison between a route with clinical measurements and routes without sermorelin-specific human absorption data.
Oral, sublingual and injected evidence compared
| Route | Sermorelin-specific human evidence | What can be concluded |
|---|---|---|
| Swallowed tablet or capsule | No established pharmacokinetic or efficacy study | Reliable systemic absorption has not been shown |
| Sublingual RDT or troche | No established human bioavailability study | Bypassing some digestion does not prove adequate exposure |
| Intravenous or subcutaneous | Older diagnostic and pediatric studies measured hormone responses | This is the route behind the published clinical record |
The table is not a dosing recommendation. Route, formulation and protocol belong to the prescriber, and data from an older pediatric or diagnostic use cannot be carried over as a promise of adult results.
What a prescription changes
Promise's current sermorelin treatment page describes an injectable vial. The formulation for an individual patient remains the reviewing prescriber's and dispensing pharmacy's call. Compounded strengths, excipients and dosage forms vary, so a label from one pharmacy cannot validate a product from another.
As of September 2026, no FDA-approved sermorelin product is currently marketed; the compounded formulation offered here is not FDA-approved. Geref's approvals were withdrawn effective June 18, 2009, and FDA later determined that the products were not withdrawn for reasons of safety or effectiveness (FDA, Federal Register, 2013). A licensed provider may still prescribe a compounded formulation when medically appropriate; that decision is between the patient and the provider.
A licensed provider reviews every Promise request and prescribes only when treatment is appropriate; not everyone qualifies. The review should account for the exact dosage form and its evidence, not treat every product bearing the molecule's name as interchangeable.
Is CJC-1295 and ipamorelin an oral alternative?
CJC-1295 and ipamorelin are not an oral alternative. They are related growth-hormone-axis compounds, not a tablet technology for sermorelin. A provider may compare that combination with sermorelin because the molecules signal the axis differently, but the comparison does not remove the route question. The current product is also an injectable vial.
If avoiding an injection is the deciding issue, the absence of route-specific human data belongs at the center of the conversation, not in the fine print. Convenience describes the experience of taking a dosage form. Pharmacokinetic evidence establishes whether the intact peptide reliably gets where it needs to go.
+